The Latest Breaking News from CMS

While national efforts to eliminate hepatitis C have faced setbacks because of increased drug use, the impact of COVID-19 and insurance complications, there’s a bright spot: Some states are now making it easier for patients to treat the disease.

States that have traditionally imposed restrictions to costly hepatitis drugs are now lifting those barriers.

U.S. stocks traded lower, with the Dow Jones dropping more than 400 points on Friday. Here are some big stocks recording losses in today’s session.

Health care providers, nursing home representatives and patient advocates say Medicare Advantage plans increasingly are ending members’ coverage for nursing home and rehabilitation services before patients are healthy enough to go home.

The proposed cuts are recommended by an advisory commission, but some lawmakers say they would devastate the home health industry.

But positive clinical trial results also renew the hopes of millions of seniors.

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen

“Today’s announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer’s disease," said Biogen CEO Michel Vounatsos.

U.S. District Judge Lisa Godbey Wood ruled August 19 in favor of Georgia after the Centers for Medicare and Medicaid Services (CMS) rescinded a Medicaid waiver for the state’s Pathways to Coverage program. Georgia brought the lawsuit after CMS under the Trump administration approved the state’s Section 1115 application for…